(Total Views: 778)
Posted On: 01/21/2017 12:42:15 PM
Post# of 72446
copy from Ihub;
Shares of the company (NASDAQ:CELG) were still down slightly at midday.
As widely expected, the company released preliminary revenue and financial guidance, maintaining its 2020 revenue target of exceeding $21 billion.
Preliminary total product sales for 2016 are expected to reach nearly $11.2 billion, a 22 percent growth year over year. Sales of Revlimid (lenalidomide) totaled nearly $7 billion, a 20 percent jump over 2015 sales, while Pomalyst (pomalidomide) sales reached $1.3 billion, a 33 percent jump over last year. Sales of Abraxane (nab-paclitaxel) reached nearly $1 billion – $973 million – and sales of Otezla – despite being only in its second year on the market, noted CEO Mark Alles – topping $1 billion and growing by 116 percent over 2015 sales.
Shares of the company (NASDAQ:CELG) were still down slightly at midday.
As widely expected, the company released preliminary revenue and financial guidance, maintaining its 2020 revenue target of exceeding $21 billion.
Preliminary total product sales for 2016 are expected to reach nearly $11.2 billion, a 22 percent growth year over year. Sales of Revlimid (lenalidomide) totaled nearly $7 billion, a 20 percent jump over 2015 sales, while Pomalyst (pomalidomide) sales reached $1.3 billion, a 33 percent jump over last year. Sales of Abraxane (nab-paclitaxel) reached nearly $1 billion – $973 million – and sales of Otezla – despite being only in its second year on the market, noted CEO Mark Alles – topping $1 billion and growing by 116 percent over 2015 sales.
(0)
(0)
